Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1126459

	registered interest
	date	14/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the process will be for patients that are refused a prescription for medical cannabis oil by their second opinion; and will he make a statement.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	254164
	answer	answer is ministerial correction date of answer 21/05/2019 answer text <p>It is right that these decisions are clinically led. As for any other medical treatment, if two clinicians are of the opinion that, on balance, it is not in the best interest of the patient to prescribe a cannabis-based product, then it will not be prescribed.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 21/05/2019 10:45:44 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1125623

	registered interest
	date	09/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) increase public consultation on the creation of interim guidance for medicinal cannabis and (b) ensure patient and health professional organisations are engaged in the Department’s working group on medicinal cannabis.
	tabling member constituency	Carshalton and Wallington
	tabling member printed	Tom Brake
	uin	252465
	answer	answer is ministerial correction date of answer 14/05/2019 answer text <p>The Department does not have a standing working group on medicinal cannabis. It has, however, held a number of engagement events with representatives of patients and health professionals in relation to this policy.</p><p>The National Institute for Health and Care Excellence (NICE) has been commissioned to update and replace interim clinical guidelines on the prescribing of cannabis-based products for medicinal use by October 2019. NICE has consulted with a wide range of stakeholders on the draft scope of the guidelines, including a stakeholder workshop held on 6 November 2018, which was attended by patient and health professional organisations. NICE is expected to issue a public consultation on draft guidelines, which will commence in summer 2019. Anyone interested in this topic, who wants to be involved in the consultation process, can register as a stakeholder at www.nice.org.uk by searching “GID-NG10124”.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 14/05/2019 15:25:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	151 label Biography information for Tom Brake

1124982

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department defines Naboline as a cannabis imitating rather than cannabis derived product.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251364
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251366 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1124983

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department is aware of any instances of (a) CBD and (b) THC being prescribed by the NHS since 1 January 2019.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251365
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The published data shows that the following number of items of Nabilone (a synthetic product which mimics tetrahydrocannabinol (THC)) and Sativex (a product containing natural THC and cannabidiol (CBD)) were dispensed in January and February 2019.</p><p> </p><table><tbody><tr><td><p> </p></td><td colspan="2"><p>Number of prescription items</p></td></tr><tr><td><p> </p></td><td><p>January 2019</p></td><td><p>February 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>44</p></td><td><p>36</p></td></tr><tr><td><p>Sativex</p></td><td><p>167</p></td><td><p>159</p></td></tr></tbody></table><p> </p><p>Data, from the NHS Business Services Authority for January and February 2019, suggest that three National Health Service prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. Additionally, the NHS Business Services Authority data report that 10 private prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in January and February 2019.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:07:00 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1124984

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, when (a) Naboline and (b) Savitex were first made available to prescribe on the NHS.
	tabling member constituency	Cardiff Central
	tabling member printed	Jo Stevens
	uin	251366
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251364 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4425 label Biography information for Jo Stevens

1123519

	registered interest
	date	29/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timeframe is for the process evaluation being undertaken by the NHS on prescribing cannabis-based products for medical use; and if he will he make a statement.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	248610
	answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 248611 question first answered 08/05/2019 13:57:42 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1123520

	registered interest
	date	29/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, who he will be engaging with in the process evaluation on prescribing cannabis-based products for medical use.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	248611
	answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>NHS England has been asked to provide an interim report to the Secretary of State for Health and Social Care by the end of May 2019. The review will be clinically led by the NHS England and NHS Improvement Medical Director and Chief Pharmaceutical Officer, drawing on further specialist support as required.</p><p>NHS England will work with patient groups and the All Party Parliamentary Group on Medical Cannabis under Prescription to identify a sample of patients that have been seeking to access cannabis-based products for medicinal use through the National Health Service. Case reviews will involve interviews with relevant individuals who are involved in the decision to prescribe cannabis-based products for medicinal use, including patients, carers and relevant trust staff.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 248610 question first answered 08/05/2019 13:57:42 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1123521

	registered interest
	date	29/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how the National Institute for Health Research will identify patients with severe intractable epilepsy to use as a placebo in research into the safety and clinical efficacy and effectiveness of cannabis-based products for medical use in humans.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	248612
	answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>To stimulate research proposals, the National Institute for Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the United Kingdom market.</p><p>The NIHR also remain open to the submission of proposals outside of these specific calls. Proposals made to NIHR are assessed for scientific rigour, which will include the design of the trials, before funding is allocated to the applicants.</p><p>The process for selecting people for inclusion in any trials will be determined by the researchers and will be dependent on the study design used in the trial.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/05/2019 13:59:06 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1123443

	registered interest
	date	26/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, how the system of second opinions on the prescribing of medical cannabis oil will be organised; and if he will make a statement.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	247998
	answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 247999 question first answered 07/05/2019 16:43:13 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning

1123444

	registered interest
	date	26/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his oral contribution of 8 April 2019, Official Report, column 26, who will be responsible for offering patients a second opinion on prescribing medical cannabis oil.
	tabling member constituency	Hemel Hempstead
	tabling member printed	Sir Mike Penning
	uin	247999
	answer	answer is ministerial correction date of answer 07/05/2019 answer text <p>In line with routine clinical practice, patients wishing to seek a second opinion on the National Health Service will be supported to do so. In the first instance, clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support trusts in identifying a suitable NHS specialist for a second opinion.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 247998 question first answered 07/05/2019 16:43:13 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1528 label Biography information for Sir Mike Penning